A steady supply of weight-loss drugs Wegovy and Mounjaro has helped lift Eucalyptus’ revenue from $78 million to $121 million ...

India's largest drugmaker by revenue Sun Pharmaceutical is aiming to launch its experimental anti-obesity and type 2 diabetes ...

Two recent documents—one from the FDA, the other from a commission organized by The Lancet Diabetes & Endocrinology—indicate ...

Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their ...

We recently published an article titled Jim Cramer Discusses These 10 Stocks & Says Bitcoin Created "Froth" In The Market. In ...

Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market ...

Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.

The GLP-1 ad wars “Healthy Skepticism” comes weeks after Eli Lilly competitor and Ozempic-maker Novo Nordisk launched a print ...

Eli Lilly launched an ad campaign on Friday, cautioning patients against the risks of unapproved weight-loss drugs in its ...

Eli Lilly’s profit doubled ... Additional approvals like that and Lilly's push to increase manufacturing should lead to ongoing, solid growth for the drugs, Edward Jones analyst John Boylan ...

New diabetes medications are pressuring Medicare Part D financially as they drive up prescription drug costs amid rising ...

As high prices and supply issues drive consumers to alternative markets for GLP-1s, physicians aren’t too interested in using ...